Pressmeddelande

Q-linea signs evaluation contract with reference laboratory network in the US

Q-linea AB (publ) (OMX:QLINEA) today announces that the company has signed an evaluation contract with a large network reference laboratory headquartered in the United States.

With the announcement of FDA clearance of the ASTar System and a Gram-negative panel (ASTar BC G- Consumable Kit), Q- linea has already signed a contract under the Early Evaluation Program with a large network reference laboratory and is in active conversations with several hospital systems for the same. Jim Kathrein, VP of US Commercial Operations, said: “Early interest in ASTar has been extremely positive and we are excited to demonstrate our fully automated rapid AST capabilities in the US market. We anticipate seeing continued strong results in line with our EAP data and European placements.”

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Source:MFN

Tillbaka

Det verkar som att du använder en annonsblockerare

Logga in på di.se

Inte prenumerant än?

Tillgång till alla nyhetsbrev med en prenumeration